So you got your company up and running and your therapeutic program is

rolling down the development pathway.  You may even have been lucky enough

to have some positive early results.  However, your current funding will

only get you so far.  You need to think about what\’s next to maximize the

value that you have created.  What will it be?

The public markets are open for business again, big pharma still has an

appetite for M&A to fill its pipeline, current investors may want to invest

more to build value or exit now to start harvesting some gains.  As a

biotech leader, what are your options and how do you maximize the value to

satisfy your stakeholders?

Come listen to our panel of experts who have been there and hear insightful

advice, real life perspectives, exciting stories and possibly some sobering

news about the high risk world of biotech.